Clinical Trials Browser

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT04969887 2026-02-27

MOST-CIRCUIT

Phase 2 Active not recruiting

240 enrolled

EndocrineNET

Genital Neoplasms, Female, Neuroendocrine Tumors

NCT04459273 2026-02-05

FAPI PET RDRC

Phase 1 Active not recruiting

26 enrolled

CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther hematologic neoplasm

Adrenal Gland Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Unknown Primary, Skin Neoplasms, Testicular Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Hematologic Neoplasms

NCT06232564 2026-01-14

PELICAN

Phase 2 Active not recruiting

20 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT03691064 2025-12-23

SALUS

Active not recruiting

1,014 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT04234568 2025-12-22

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Phase 1 Active not recruiting

31 enrolled 16 charts

EndocrineNET

Neuroendocrine Tumors

Clinical Trials

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors

STARTRK-2

MOST-CIRCUIT

FAPI PET RDRC

PELICAN

SALUS

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors